NOVARTIS N (NOT.SG)
NOVARTIS N (NOT.SG) operates in Diversified Metals & Mining.
NOVARTIS N (NOT.SG) (NOT) - Total Liabilities
Latest total liabilities as of September 2024: €60.08 Billion EUR
Based on the latest financial reports, NOVARTIS N (NOT.SG) (NOT) has total liabilities worth €60.08 Billion EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NOVARTIS N (NOT.SG) - Total Liabilities Trend (2014–2023)
This chart illustrates how NOVARTIS N (NOT.SG)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NOVARTIS N (NOT.SG) Competitors by Total Liabilities
The table below lists competitors of NOVARTIS N (NOT.SG) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Australasian Metals Ltd
AU:A8G
|
Australia | AU$210.16K |
|
Badlands Resources Inc
PINK:BDLNF
|
USA | $3.82 Million |
|
Westar Resources Ltd
AU:WSR
|
Australia | AU$114.20K |
|
Galera Therapeutics Inc
PINK:GRTX
|
USA | $153.77 Million |
|
OSHKOSH (OK3.SG)
STU:OK3
|
Germany | €5.77 Billion |
|
Jaya Swarasa Agung PT
JK:TAYS
|
Indonesia | Rp308.47 Billion |
|
Nickelsearch Ltd
AU:NIS
|
Australia | AU$2.63 Million |
|
Aquaporin AS
CO:AQP
|
Denmark | Dkr101.12 Million |
Liability Composition Analysis (2014–2023)
This chart breaks down NOVARTIS N (NOT.SG)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NOVARTIS N (NOT.SG)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NOVARTIS N (NOT.SG) (2014–2023)
The table below shows the annual total liabilities of NOVARTIS N (NOT.SG) from 2014 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €53.20 Billion | -8.33% |
| 2022-12-31 | €58.03 Billion | -9.29% |
| 2021-12-31 | €63.97 Billion | -10.04% |
| 2020-12-31 | €71.11 Billion | +13.20% |
| 2019-12-31 | €62.82 Billion | -6.06% |
| 2018-12-31 | €66.87 Billion | +13.63% |
| 2017-12-31 | €58.85 Billion | +6.55% |
| 2016-12-31 | €55.23 Billion | +1.47% |
| 2015-12-31 | €54.43 Billion | -0.20% |
| 2014-12-31 | €54.54 Billion | -- |